Halaven (Eribulin Mesylate)

Halaven (eribulin mesylate) is a microtubule inhibitor used for the treatment of patients with:

• Metastatic breast cancer who have previously been treated with at least 2 chemotherapeutic regimens for the treatment of metastatic disease. Before therapy, it should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.
• Unresectable or metastatic liposarcoma, who have previously been treated with an anthracycline-containing regimen.

Recommended Dosage:
The recommended dosage of Halaven injection is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. Dosage can be reduced in patients with hepatic impairment or with moderate or serious renal impairment. It is not advisable to mix it with other drugs or administer it with dextrose-containing solutions. Obtain complete blood cell counts and assess for peripheral neuropathy before each dose.
The recommended dose of Halaven injection in patients with mild hepatic impairment (Child-Pugh A) is 1.1 mg/m2, in patients with moderate hepatic impairment (Child-Pugh B) is 0.7 mg/m2, and in patients with moderate or severe renal impairment (creatinine clearance (CLcr) 15-49 mL/min) is 1.1 mg/m2 administered intravenously over 2-5 minutes on Days 1 and 8 of a 21-day cycle.

• Treatment with Eribulin 1 mg/2 mL may cause serious neutropenia, lowering white blood cells (WBCs) and increasing infection risk. Monitor blood counts before and during treatment. Delay or reduce the dose in case neutropenia occurs. Prompt medical attention is needed if patients show fever, chills, or infection.
• This therapeutic drug can cause peripheral neuropathy, including tingling, numbness, or pain in the hands or feet. Signs and symptoms may worsen with the ongoing use of treatment. Assess regularly for signs. In case neuropathy becomes critical, adjust or stop treatment depending on clinical judgment and patient tolerance.
• This medicine may increase the QT interval, which can be responsible for causing irregular heartbeat. Use it cautiously in those with heart conditions or those taking QT-prolonging medicines. Monitor ECG if required. Discontinue treatment if patients experience dizziness, syncope, or significant heart rhythm disturbances.
• Patients of reproductive potential should use an appropriate contraception method during and after treatment. This medicine may harm reproductive health or the development of the fetus. Discuss fertility preservation options before starting treatment. Both men and women must refrain from trying for a baby for some time after treatment has been administered.
• Eribulin is likely to pose significant risks to the child if it is administered during pregnancy. It should not be administered to pregnant women except in critically necessary cases. Counsel women who can potentially conceive on the risks related to treatment, and advise them to undergo a test for pregnancy before the initiation of treatment.
• It is unknown if this medicine passes into human milk. Because of potential serious side effects in nursing infants, avoid breastfeeding during treatment and for a period after the final dose. Discuss alternative options for feeding the patient.
• The safety and effectiveness of Eribulin 1 mg/2 mL injection have not been established in pediatric patients. Therefore, do not use this medicine in children or adolescents under 18 years. Pediatric dosing and toxicity remain inadequately studied.
• Elderly patients may have increased sensitivity to this medicine, including heightened risk for fatigue and neutropenia. Monitor closely for side effects. Dose adjustments may be required depending on renal function, tolerance, and overall health condition of the geriatric patient.

What documents are required to import HALAVEN to India?

HALAVEN (eribulin mesylate) injections can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is HALAVEN available in India?

HALAVEN (eribulin mesylate) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Halaven in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

HALAVEN can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of HALAVEN (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Halaven 1 mg/2 mL injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source HALAVEN (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Halaven®?

Eribulin mesylate is the Generic Name for the trade name drug Halaven®.

What is the Manufacturer's Name of Halaven®?

Halaven® is jointly manufactured by Eisai Co., Ltd.

Is Halaven approved by the FDA?

Yes, Halaven® is approved by the FDA. Date of first approval: November 15, 2010.

What is the dosage and form of Halaven® supplied?

Halaven is supplied in Injection: 1 mg per 2 mL (0.5 mg per mL) eribulin mesylate in a single-dose vial for intravenous (IV) use.

What are the most common side effects of Halaven® 1 mg/2 mL injections?

The most common side effects of Halaven® injection are anemia, neutropenia, asthenia/fatigue, alopecia, nausea, peripheral neuropathy, constipation, abdominal pain, and pyrexia.

How much does Halaven® 1 mg/2 mL injection cost in India?

Prices of Halaven injections may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Halaven 1 mg/2 mL cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Halaven® 1 mg/2 mL injections be available in SAARC countries?

Apart from Gulf countries, Halaven® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Halaven® injections in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Halaven® 1 mg/2 mL injections online in India?

Yes, one can buy Halaven 1 mg/2 mL online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Halaven® injections through legal channels.

What are the storage conditions of Halaven® 1 mg/2 mL injections?

Store vials at 25°C (77°F); excursions permitted to 15-30° C (59-86° F). It is not advisable to freeze or refrigerate the medicine. Store the vials in their original cartons.